About
Technology
Issues
FAQ
Search
Profile
Schools
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Scientometrics
Avg. Impact Factor
Discipline Ranks
h
-index
g
-index
★★
Articles
★★★
Articles
Article Citations
Citation Distribution
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Institutions
›
Horizon Therapeutics
›
top-articles
Horizon Therapeutics
21
(top 1%)
papers
386
(top 1%)
citations
11
(top 1%)
h
-index
17
(top 1%)
g
-index
34
all documents
410
doc citations
234
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
American Journal of Gastroenterology
2012
85
2
American Society for Pain Management Nursing Position Statement: Pain Management in Patients with Substance Use Disorders
Pain Management Nursing
2012
57
3
Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations
Journal of Pain
2020
37
4
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout
Hypertension
2019
31
5
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Arthritis Research and Therapy
2018
28
6
Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout
Arthritis Research and Therapy
2017
25
7
Pharmacokinetics of Modified‐Release Prednisone Tablets in Healthy Subjects and Patients With Rheumatoid Arthritis
Journal of Clinical Pharmacology
2013
24
8
Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis
RMD Open
2015
19
9
Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase
Rheumatology and Therapy
2019
17
10
Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary
Metabolic Brain Disease
2016
16
11
The Relative Bioavailability and Effects of Food and Acid‐Reducing Agents on Filgotinib Tablets in Healthy Subjects
Clinical Pharmacology in Drug Development
2019
16
12
Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone
Scandinavian Journal of Rheumatology
2015
13
13
What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?
Arthritis Care and Research
2015
10
14
Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase
Rheumatology
2019
8
15
Evaluation of Proposed Criteria for Remission and Evidence‐Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout
ACR Open Rheumatology
2019
7
16
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects
Clinical Pharmacology in Drug Development
2020
7
17
Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate
Molecular Genetics and Metabolism Reports
2015
6
18
AB0876 GOUT CAUSING URATE CARDIAC VEGETATIONS: SUMMARY OF PUBLISHED CASES
2019
3
19
THU0416 Rapid tophus resolution in chronic refractory gout patients treated with pegloticase
2017
1
20
AB0426 Time to Event Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared To, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving DMARDS over 1 Year
Annals of the Rheumatic Diseases
2014
0
21
Response to ‘Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 studies has not been Justified and on Balance is Not Useful’ by D.A. Parasrampuria and L.Z. Benet
Basic and Clinical Pharmacology and Toxicology
2015
0
22
THU0448 Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi: response to pegloticase
2017
0
23
Facts Concerning Duexis Prescribing Habits Related to Combination Therapies
JAMA Internal Medicine
2017
0
24
THU0438 Lack of predictive value of the NIAID/FAAN criteria to identify subjects with evidence of immune activation after receiving pegloticase for chronic refractory gout
2017
0
25
THU0449 Evidence based development of criteria for complete response in patients with chronic refractory gout
2017
0
26
AB0892 Progressive clinical benefit in chronic refractory gout patients achieving a persistent urate lowering effect from pegloticase treatment
2017
0
27
FRI0237 Pegloticase treatment significantly decreases mean arterial blood pressure in patients with chronic gout
2018
0
28
AB0875 GOUT, NOT JUST A DISEASE OF THE FOOT. LITERATURE REVIEW OF SYSTEMIC DEPOSITION OF URATE
2019
0
29
OP0051 DEVELOPMENT OF A MULTIVARIABLE IMPROVEMENT MEASURE FOR GOUT
2019
0
30
SAT0434 A TRANSIENT DECREASE IN SERUM URATE CHANGES THE CLINICAL TRAJECTORY OF SUBJECTS WITH ADVANCED GOUT
2019
0
31
SAT0370 Association of renal dysfunction and development of tophi in subjects with chronic refractory gout and response to treatment with pegloticase
2018
0
32
OP0184 The frequency of flares in subjects with chronic refractory gout treated with pegloticase is related to variation in the level of plasma urate
2018
0
33
SAT0356 Factors influencing tophus resolution in patients with persistent urate lowering responses to pegloticase
2018
0
34
SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
Journal of the Endocrine Society
2019
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.